Experimental muscular dystrophy therapy replenishes muscle stem cells | Incidence of Pseudomonas aeruginosa septicemia rising in U.S. | Phase I study finds novel cancer drug safe in patients with leukemia
Web Version
September 9, 2014
AABB SmartBrief
News for the transfusion medicine and cellular therapy community

Top StorySponsored By
Experimental muscular dystrophy therapy replenishes muscle stem cells
Scientists with the Sanford-Burnham Medical Research Institute in La Jolla, Calif., found that STAT3-inhibiting drugs helped repair muscle tissue in mouse models of muscular dystrophy and in tests involving human muscle cells. The compounds replenished supplies of muscle stem cells, according to the study in the journal Nature Medicine. Medical News Today (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
Are you ready for your CAP Inspection?
Your laboratory's CAP inspection is right around the corner — are you ready? Download our latest White Paper to learn the most common deficiencies found in 2013 CAP Inspections, tips to help you meet accreditation standards, and how Title21 Software can help you painlessly meet even the most common deficiencies. Download the free White Paper now.
Science & HealthSponsored By
Incidence of Pseudomonas aeruginosa septicemia rising in U.S.
A study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy found a 51.2% increase in the number of Pseudomonas aeruginosa septicemia cases among hospitalized adults in the U.S. from 2005 to 2010. "It's outpacing the general trend of septicemia as a whole, which may be an indicator that the increase in septicemia might be related to multidrug-resistant pathogens," said researcher Brian Werth of the University of Washington. Healio (free registration)/Infectious Disease News (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
Phase I study finds novel cancer drug safe in patients with leukemia
The experimental drug CPI-613, which targets the mitochondria of cancer cells, was found safe in patients with leukemia, according to a Phase I study in the journal Clinical Cancer Research. Of the 21 patients who finished the trial, 29% experienced benefits, including remissions of two and three years. Science World Report (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
Studies look at recurrent Clostridium difficile infection treatment, effects
University of Indiana researchers reported prophylactic oral vancomycin may protect against recurrent Clostridium difficile infection. A second study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy found recurrent C. diff infections were linked with worse outcomes and increased resource usage, in comparison with non-recurrent infection. MedPage Today (free registration) (9/7), Healio (free registration) (9/7)
Share: LinkedInTwitterFacebookGoogle+Email
FREE Benchmark Data: Remote Blood Storage
Do you know how quickly blood is available to your ER and Trauma units? Take this quick 7-question survey to see how you compare to other blood banks in such mission critical standards as order-to-transfusion time, security and traceability. The survey takes less than two minutes, your specific facility data remains completely confidential and you can see all the benchmarking data free after completing the survey. See how your blood bank ranks…
Emerging Trends
New test detects antibiotic-resistant infections in hours
Oregon State Public Health Laboratory researchers have designed the Carba NP test to detect carbapenem-resistant Enterobacteriaceae within hours. A study confirming the reliability of the test was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Business Standard (India)/Asian News International (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
Study: Only dozens of genes needed to identify all tuberculosis strains
U.K. researchers analyzed more than 90,000 mutations in the genes of Mycobacterium tuberculosis and found that only 62 were needed to classify the global family of strains. The development of the genetic "bar code" can be used to advance research and track how tuberculosis spreads globally, according to the study in the journal Nature Communications. Medical News Today (9/5)
Share: LinkedInTwitterFacebookGoogle+Email
PBM Workshop Highlights Business Case and Business Plan for PBM
A forerunner to the AABB Annual Meeting, the PBM Preconference Workshop: Better Care and Better Patient Outcomes is a full-day workshop that will highlight business cases and the development of business plans around PBM. Expert speakers will discuss clinical and operational considerations for PBM programs. Register today for the PBM Workshop, Friday, October 24.
Industry News & Practice
Partnership aims to build hemophilia registry
The "My Life, Our Future" program, launched by the National Hemophilia Foundation, the Puget Sound Blood Center, Biogen Idec and the American Thrombosis and Hemostasis Network, is offering free genotyping to hemophilia patients to create a registry containing data to be used for research and drug development. The registry will contain data on the genetic makeup of each patient, including clotting-factor mutations, and researchers can apply to access data and samples from the registry. Pittsburgh Post-Gazette (9/9)
Share: LinkedInTwitterFacebookGoogle+Email
Rockland receives NIH grant to develop sickle cell point-of-care device
The National Institutes of Health's National Heart, Lung, and Blood Institute has awarded Rockland Immunochemicals a $224,473 grant to develop an antibody-based point-of-care device to diagnose sickle cell disease in infants and young children. Genetic Engineering & Biotechnology News (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
Diagnostic tool designed to identify cancer in blood samples
Exosome Sciences and its parent company, Aethlon Medical, have created a diagnostic tool that they say could spot several types of cancer using blood specimens. The highly sensitive test, which has been subjected to initial validation studies, could help improve the monitoring of disease progression and patient response to treatments, according to Exosome researchers. San Diego Business Journal (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
The Buzz
Expedite Your Path to BLA/IND Approval
Let AABB Consulting Services help you develop and implement an efficient and effective plan for a successful application. Our team of experts will identify and address areas of concern so you can move forward with confidence. Contact us today for a consultation to see how we can assist you.
Government & Regulatory
U.K. health panel endorses eculizumab for rare blood disorder
The National Institute for Health and Care Excellence's Highly Specialized Technologies Evaluation Committee has recommended Alexion Pharmaceuticals' eculizumab, or Soliris, for the treatment of atypical hemolytic uremic syndrome. The drug has been approved in the U.S., Europe and Japan. Outsourced Pharma (9/8)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
Reminder: Review proposed AABB Bylaws amendments and vote at Annual Meeting
AABB encourages all voting members to review the proposed amendments to the association's existing bylaws. There will be a vote on the proposed changes at the 2014 business meeting at 1 p.m. on Tuesday, Oct. 28, during the AABB Annual Meeting in Philadelphia. Notice of the proposed changes and additional information are posted on the AABB website.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Lead Medical TechnologistUMass Memorial Health CareWorcester, MA
Medical Affairs DirectorBlood Systems, Inc.Scottsdale, AZ
Business Systems Analyst IIBlood Systems, Inc.Scottsdale, AZ
Sr. Medical Technologist/ Blood BankBrigham and Women's Faulkner Hospital, MA
Click here to view more job listings.
I must govern the clock -- not be governed by it."
-- Golda Meir,
former Israeli prime minister
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information